AVITA Medical (RCEL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the Medical First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please note that today's conference is being recorded. I will now hand the conference over to your first speaker for today, Jessica Eckberg. Please go ahead. Speaker1 Thank you ...

Q1 2025 Earnings Presentation May 8, 2025 Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as "anticipate," "expect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 85-1021707 (IRS Employer Identification No.) 28159 Avenue Stanford or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...

Exhibit 99.1 AVITA Medical Reports First Quarter 2025 Financial Results VALENCIA, Calif., May 8, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments "We've transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lea ...

VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.c ...

Shares of Avita Medical Inc. (RCEL) have gained 20.5% over the past four weeks to close the last trading session at $10.22, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.60 indicates a potential upside of 52.6%.The average comprises five short-term price targets ranging from a low of $11 to a high of $21, with a standard deviation of $3.71. While the lowest estimate indica ...

It’ll be pretty easy to forget the sequential sales decline in Q4 2024 if 2025 shows the consisted sequential sales growth shareholders have been hoping for. As for the FebruaryAnalyst’s Disclosure: I/we have a beneficial long position in the shares of RCEL, STXS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company w ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Confe ...

Q4 2024 Earnings Presentation February 13, 2025 Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 P 3 WHO WE ARE Accelerated Recovery with Therapeutic Acute Wound Care OUR MISSION Our mission is to position AVITA Medical as a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. OUR IMPACT This presentation and the accompanying oral commentary are "forward-looki ...

Revenue Growth - Total revenues increased by 28.1%, or $14.1 million, to $64.3 million for the year ended December 31, 2024, compared to $50.1 million in 2023[181]. - Commercial revenue was $64.0 million for the year ended December 31, 2024, an increase of 29% compared to $49.8 million in 2023, driven by deeper penetration within customer accounts[181]. - Total net revenues rose by 46%, or $15.7 million, to $50.1 million for the year ended December 31, 2023, driven by deeper penetration within customer accounts and the launch of full-thickness skin defects[192]. Profitability and Margins - Gross profit margin improved to 85.8% from 84.5% in the prior year, attributed to increased revenues and production volume[182]. - Gross profit margin increased by 2% to 84.5% compared to 82.4% in the previous year, attributed to higher production and lower shipping costs[193]. Operating Expenses - Total operating expenses rose by 29%, or $25.3 million, to $111.8 million compared to $86.4 million in 2023[184]. - Total operating expenses increased by 46%, or $27.3 million, to $86.4 million, compared to $59.1 million in the year ended December 31, 2022[195]. - Sales and marketing expenses surged by 56%, or $20.9 million, to $58.2 million, primarily due to increased salaries, commissions, and expansion of the sales force[185]. - Sales and marketing expenses surged by 70%, or $15.4 million, to $37.3 million, primarily due to higher salaries, benefits, and costs associated with the commercial launch of new products[196]. - General and administrative expenses increased by 17%, or $4.9 million, to $33.1 million, driven by higher salaries and stock-based compensation[186]. - Research and development expenses decreased by 2%, or $0.5 million, to $20.3 million, mainly due to lower professional fees offset by increased salaries[187]. - Research and development expenses rose by 50%, or $6.9 million, to $20.8 million, driven by higher clinical trial costs and the development of the next generation RECELL GO[198]. Net Loss - Net loss increased by $26.5 million to $61.8 million for the year ended December 31, 2023, compared to a net loss of $35.4 million in the previous year[190]. Cash and Debt - As of December 31, 2024, the company had approximately $14.1 million in cash and cash equivalents and $21.8 million in marketable securities[202]. - The company entered into a Credit Agreement on October 18, 2023, providing a five-year senior secured credit facility of up to $90 million, with $40 million borrowed on the closing date[203]. - Interest expense rose by approximately $4.2 million due to long-term debt related to the OrbiMed Credit Agreement, totaling $40.0 million[188]. - Net cash used in operations was $48.9 million for the year ended December 31, 2024, compared to $38.0 million in the previous year, primarily due to higher operating costs[207]. Product Approvals and Launches - The FDA approved RECELL GO mini, expected to launch in Q1 2025, targeting smaller wounds[179]. - Cohealyx received FDA 510(k) clearance, with full commercialization efforts planned for Q2 2025[178]. Revenue Recognition and Accounting - Revenue is primarily generated from the sale of RECELL EOU, RPK, and PermeaDerm products to hospitals and distributors[217]. - Revenue recognition for RECELL GO system is disaggregated between ASC 606 for RPK and ASC 842 for RPD[218]. - Most contracts have a single performance obligation, with revenue recognized when control of goods or services is obtained[222]. - The lease component (RPD) is accounted for under ASC 842, while the non-lease component (RPK) is accounted for under ASC 606[226]. - Assets in the lease program are depreciated over the useful life of the RPD device, which is 200 uses[227]. - Share-based compensation is measured on a graded-vesting method, with performance-based awards estimated at each reporting date[229]. - Long-term debt is accounted for using the fair value option, with changes in fair value reported in earnings[233]. - Deferred tax assets and liabilities are recognized for future tax consequences, measured using enacted tax rates[237]. - The company regularly reviews uncertain tax positions and recognizes tax benefits when more-likely-than-not that the position will be sustained[238]. - Recent accounting pronouncements are discussed in Note 2 of the Consolidated Financial Statements[240].